Irbesartán/Hidroclorotiazida Alter

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartán/Hidroclorotiazida Alter, is an angiotensin II receptor blocker and thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Irbesartán/Hidroclorotiazida Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage high blood pressure within the renin‑angiotensin‑aldosterone system pathway. - Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Secondary hypertension: assists in controlling blood pressure when it results from another underlying condition. - High cardiovascular‑risk patients: contributes to overall risk reduction by maintaining optimal blood pressure.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or weakness. - Increased urination. - Electrolyte disturbances, especially low potassium. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance. - Acute kidney injury or worsening renal function. - Hyperkalemia when combined with potassium‑sparing agents. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Blood dyscrasias including leukopenia or thrombocytopenia. - Hepatic dysfunction or jaundice.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Electrolyte and renal function checks: regularly evaluate potassium, sodium, and creatinine. - Contraindication in severe renal impairment: avoid or adjust dose. - Caution in diabetes mellitus: monitor blood glucose as diuretic may affect control. - Pregnancy and lactation: safety category unknown; use only if benefits outweigh risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines; careful review is essential. Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effects on blood pressure and renal function. - Lithium: increased lithium levels and toxicity. - NSAIDs (high dose): can reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may require dose adjustment to avoid hypotension. - CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma concentrations. - Antidiabetic agents: diuretic effect may affect glucose control. - Anticoagulants: thiazide component may enhance anticoagulant effect. - Digoxin: electrolyte changes can predispose to digoxin toxicity.